Not only is the biotech trading at a discount to its fundamental value, but it's key product is about to be commercialised and the firm could find itself a takeover target. Speculation is that its licencing partner, pharmaceutical giant Eli Lilly, will move when Acrux receives the final approval from US regulators for its spray-on testosterone product Axiron before March next year. At that point Eli Lilly has to fork out $U87 million ($89 Million) to Acrux. Brokers covering the stock rate it a "BUY", with an average price target of $3.46.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.001(6.25%) |
Mkt cap ! $6.116M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.5¢ | $1.574K | 104.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 609316 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 388346 | 2 |
View Market Depth
| Last trade - 11.39am 26/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |